ArriVent BioPharma Earnings Estimate
| AVBP Stock | 22.46 0.04 0.18% |
ArriVent BioPharma Earnings Estimation Breakdown
The calculation of ArriVent BioPharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ArriVent BioPharma is estimated to be -0.9183 with the future projection ranging from a low of -1.05 to a high of -0.77. Please be aware that this consensus of annual earnings estimates for ArriVent BioPharma Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.05 Lowest | Expected EPS | -0.77 Highest |
ArriVent BioPharma Earnings Projection Consensus
Suppose the current estimates of ArriVent BioPharma's value are higher than the current market price of the ArriVent BioPharma stock. In this case, investors may conclude that ArriVent BioPharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ArriVent BioPharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 12 | 68.94% | 0.0 | -0.9183 | -4.15 |
ArriVent BioPharma Earnings per Share Projection vs Actual
Actual Earning per Share of ArriVent BioPharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ArriVent BioPharma Common predict the company's earnings will be in the future. The higher the earnings per share of ArriVent BioPharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.ArriVent BioPharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as ArriVent BioPharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ArriVent BioPharma should always be considered in relation to other companies to make a more educated investment decision.ArriVent Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact ArriVent BioPharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-10 | 2025-09-30 | -0.79 | -0.83 | -0.04 | 5 | ||
2025-08-11 | 2025-06-30 | -0.76 | -0.9 | -0.14 | 18 | ||
2025-05-12 | 2025-03-31 | -0.73 | -1.9 | -1.17 | 160 | ||
2025-03-03 | 2024-12-31 | -0.46 | -0.6 | -0.14 | 30 | ||
2024-11-15 | 2024-09-30 | -0.54 | -0.61 | -0.07 | 12 | ||
2024-08-14 | 2024-06-30 | -0.51 | -0.65 | -0.14 | 27 | ||
2024-05-08 | 2024-03-31 | -1.2963 | -0.7 | 0.5963 | 46 | ||
2024-03-28 | 2023-12-31 | -1.1 | -0.7 | 0.4 | 36 |
About ArriVent BioPharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of ArriVent BioPharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current ArriVent BioPharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as ArriVent BioPharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -214.5 M | -225.2 M | |
| Earnings Yield | (0.09) | (0.09) | |
| Price Earnings Ratio | (11.98) | (12.58) | |
| Price Earnings To Growth Ratio | (0.67) | (0.63) |
Pair Trading with ArriVent BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
The ability to find closely correlated positions to ArriVent BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma Common to buy it.
The correlation of ArriVent BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.